Anita Banerjee, MD
Cardiovascular Disease · Springfield, VANPI 1073630273
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,763 of the $8,992 with a category attached, or 75.2%. It is spread thinly across 36 manufacturers, the largest accounting for just 17.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $3,707 and has fallen 66.0% since, to $1,262 in 2025.
Across 320 payments — averaging $28.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Johnson & Johnson$1K
- Bard Peripheral Vascular, Inc.$1K
- Novartis$678
- Merck$621
- Boston Scientific$532
- plus $3K from 30 others
Across 10 payments — averaging $4079.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$38K
- Boehringer Ingelheim Pharma GmbH & Co.kg$2K
- Boehringer Ingelheim France S.a.s.$290
- Boehringer Ingelheim Canada Ltd.ltee$210
What the payments were for
- Travel & lodging$2,21825%
- Food & beverage$6,76375%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 25 | $1,546 |
| Johnson & Johnson | 76 | $1,338 |
| Bard Peripheral Vascular, Inc. | 15 | $1,327 |
| Novartis | 36 | $678 |
| Merck | 34 | $621 |
| Boston Scientific | 12 | $532 |
| Pfizer | 19 | $460 |
| E.r. Squibb & Sons, L.L.C. | 13 | $237 |
| Biotronik Inc. | 4 | $199 |
| Coala Life Inc | 6 | $181 |
| Esperion Therapeutics, Inc. | 10 | $170 |
| Atricure, Inc. | 5 | $165 |
| AstraZeneca | 9 | $163 |
| Novo Nordisk | 7 | $146 |
| Sanofi-aventis U.S. LLC | 5 | $141 |
| Abbott | 5 | $107 |
| Medicomp Inc | 4 | $99 |
| Cardinal Health 200 LLC | 1 | $98 |
| Amgen | 5 | $88 |
| Biosense Webster, Inc. | 3 | $86 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $75 |
| Scpharmaceuticals Inc. | 3 | $56 |
| Impulse Dynamics (USA) Inc. | 1 | $53 |
| Baxter Healthcare | 1 | $52 |
| Actelion Pharmaceuticals US, Inc. | 2 | $51 |
| Boehringer Ingelheim | 1 | $49 |
| Abiomed | 3 | $48 |
| BD | 2 | $46 |
| Kestra Medical Technology Services, Inc. | 2 | $41 |
| Lilly USA, LLC | 1 | $28 |
| Cardiva Medical, Inc. | 1 | $20 |
| Cvrx, Inc. | 1 | $19 |
| Heartflow, Inc. | 1 | $19 |
| Bayer | 1 | $18 |
| Philips North America LLC | 1 | $17 |
| Vivaquant Inc, Dba Rhythm Express | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VenaSeal$942
- Venclose Maven Catheter$901
- XARELTO$487
- Varithena Administration Pack$245
- ELIQUIS$124
How this compares
$8,992 in reported general payments places this provider in the 85th percentile of 548 cardiovascular disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 222 | $273,983 |
| EntrestoSacubitril/Valsartan | 60 | $77,299 |
| XareltoRivaroxaban | 38 | $52,267 |
| OzempicSemaglutide | 12 | $11,249 |
| VascepaIcosapent Ethyl | 20 | $9,200 |
| Flecainide Acetate | 48 | $3,523 |
| Metoprolol Succinate | 173 | $3,363 |
| Carvedilol | 239 | $1,805 |
| Atorvastatin Calcium | 145 | $1,578 |
| Bumetanide | 31 | $1,540 |
| Amlodipine Besylate | 168 | $1,092 |
| Losartan Potassium | 105 | $995 |
| Valsartan | 26 | $878 |
| Rosuvastatin Calcium | 84 | $809 |
| Midodrine Hcl | 12 | $606 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $460 | $273,983222 claims |
| NovartisEntresto | $678 | $77,29960 claims |
| Johnson & JohnsonXarelto | $1,338 | $52,26738 claims |
| Novo NordiskOzempic | $146 | $11,24912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 548 cardiovascular disease providers in Virginia.
Other cardiovascular disease in Springfield
- George VetrovecRichmond$2.3M
- Hamid TaheriManassas$501K
- Cyrus HadadiNorfolk$360K
- Michael AyersCharlottesville$305K
- David LimCharlottesville$264K
- Alexander TruesdellFalls Church$167K
- Antonio AbbateCharlottesville$161K
- Christopher OconnorFalls Church$161K
- Roberta ChapmanGloucester$155K
- Shaival KapadiaColonial Heights$115K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.